The European Medicines Agency (EMA) has agreed to review Prilenia Therapeutics’ application seeking approval of pridopidine, an oral therapy candidate for adults with Huntington’s disease, the company announced. The regulatory application is based on safety and efficacy data from pridopidine’s clinical development program, which showed the therapy…
People with Huntington’s disease have significantly higher levels of the proinflammatory molecule interleukin-6 (IL-6) and the anti-inflammatory molecule IL-10 in their blood relative to healthy people, according to a review study. The IL-6 difference was true for both pre-manifest patients — those carrying Huntington’s-causing mutations, but not yet having…
Nonprofits around the world are hoping to “turn up the global volume” for Huntington’s Disease Awareness Month, an annual event in May to call attention to the disease, estimated to affect up to 7 per 100,000 people globally. In the U.S., about 41,000 Americans are affected by the disease,…
Get regular updates to your inbox.